Search research articles
Contact Us
Filters
Showing results (531-540 of 605) with videos related to
Page
of 61
Sort By:
Actas Urologicas Espanolas
|
October 31, 2013
Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program
J Rubio-Briones, J Casanova, R Dumont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 2024
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial
A Alvarez Secord, S N Lewin, C G Murphy, et al.
Bone Marrow Transplantation
|
February 26, 2024
Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial
María E Martínez-Muñoz, Concepción Payares-Herrera, Inés Lipperheide, et al.
Anti-Cancer Drugs
|
April 23, 2019
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer
Ignacio Romero, Pedro Mallol, Ana Santaballa, et al.
Gynecologic Oncology
|
May 11, 2023
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer
I Vergote, E Van Nieuwenhuysen, A Casado, et al.
Oncogene
|
March 13, 2021
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B
Alfonso E Bencomo-Alvarez, Andres J Rubio, Idaly M Olivas, et al.
ESC Heart Failure
|
March 28, 2025
Early diuretic response and outcome prediction in ambulatory worsening heart failure: Natriuresis versus diuresis
M Cobo Marcos, R de la Espriella, I Zegri-Reiriz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E Pujade-Lauraine, F Selle, G Scambia, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 2021
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
Ignace Vergote, Isabelle Ray-Coquard, Daniel M Anderson, et al.
Actas Urologicas Espanolas
|
November 25, 2015
A Preliminary Study of the Ability of the 4Kscore test, the Prostate Cancer Prevention Trial-Risk Calculator and the European Research Screening Prostate-Risk Calculator for Predicting High-Grade Prostate Cancer
Á Borque-Fernando, L M Esteban-Escaño, J Rubio-Briones, et al.
Page
of 61
Search research articles
Search
Showing results (531-540 of 605) with videos related to
Sort By:
Page
of 61
Actas Urologicas Espanolas
|
October 31, 2013
Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program
J Rubio-Briones, J Casanova, R Dumont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 2024
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial
A Alvarez Secord, S N Lewin, C G Murphy, et al.
Bone Marrow Transplantation
|
February 26, 2024
Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial
María E Martínez-Muñoz, Concepción Payares-Herrera, Inés Lipperheide, et al.
Anti-Cancer Drugs
|
April 23, 2019
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer
Ignacio Romero, Pedro Mallol, Ana Santaballa, et al.
Gynecologic Oncology
|
May 11, 2023
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer
I Vergote, E Van Nieuwenhuysen, A Casado, et al.
Oncogene
|
March 13, 2021
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B
Alfonso E Bencomo-Alvarez, Andres J Rubio, Idaly M Olivas, et al.
ESC Heart Failure
|
March 28, 2025
Early diuretic response and outcome prediction in ambulatory worsening heart failure: Natriuresis versus diuresis
M Cobo Marcos, R de la Espriella, I Zegri-Reiriz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E Pujade-Lauraine, F Selle, G Scambia, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 2021
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
Ignace Vergote, Isabelle Ray-Coquard, Daniel M Anderson, et al.
Actas Urologicas Espanolas
|
November 25, 2015
A Preliminary Study of the Ability of the 4Kscore test, the Prostate Cancer Prevention Trial-Risk Calculator and the European Research Screening Prostate-Risk Calculator for Predicting High-Grade Prostate Cancer
Á Borque-Fernando, L M Esteban-Escaño, J Rubio-Briones, et al.
Page
of 61